• 出版社/出版日：Mordor Intelligence / 2019年12月26日
|Single User||￥480,250 (USD4,250)||▷ お問い合わせ|
|Multi User||￥536,750 (USD4,750)||▷ お問い合わせ|
|Global Site License||￥847,500 (USD7,500)||▷ お問い合わせ|
Recombinant Protein Market – Growth, Trends, and Forecast (2019 – 2024)
The growth of the recombinant protein market is attributed due to increased expenditure in R&D, the growing prevalence of chronic diseases, rising inclination toward biologics and biosimilars, and advanced recombinant products.
R&D is defined as the process of creating new products, processes, and technologies that can be used and marketed for mankind’s benefit in the future. New drugs serving unmet medical needs are one of the key value drivers of research-based pharmaceutical companies. The rate of growth in R&D funding, in 2015, and the location of that growth are both significant. Trends are showing a return to growth, with only minor caution, across most areas of R&D spending. The increase in R&D investment in Asia, particularly China, and the consecutive annual growth in R&D spending in North America indicates a period of stability, security, and healthy competition across industrial sectors. As per the 2016 Global R&D Funding Forecast, this year, sponsored by the Industrial Research Institute (IRI), Washington, DC, reveals that global R&D investments may increase by 3.5% in 2016, to a total of USD 1.948 trillion in purchasing power parity (PPP) values for more than 110 countries having significant R&D investments (more than USD 100 million). Thus, increased research and R&D investments in the life sciences industry are augmenting the growth of the market.
Scope of the Report
As per the scope of the report, the term recombinant proteins are encoded by recombinant DNA, which involves insertion of DNA, encoding that particular protein into bacterial or mammalian cells. The protein is then purified, after getting expressed in these cells. Recombinant protein is produced either by molecular cloning or through polymerase chain reaction (PCR).
Key Market Trends
The Drug Discovery Segment is Expected to Grow at the Fastest Rate, during the Forecast Period
The therapeutic application segment held a considerable share in 2018. Biopharmaceuticals have become bestsellers for the treatment of chronic conditions diabetes & cancers, and are forging their ways in the field of inflammatory disease management, such as psoriasis, multiple sclerosis, rheumatic diseases, and inflammatory bowel diseases. The introduction of recombinant proteins has revolutionized the development and manufacturing processes of biotherapeutics. The number of recombinant drugs is expected to grow further as multiple biologics & vaccines consisting of recombinant proteins are currently in the pipeline and are expected to get FDA approval. In the year 2018, FDA approved Leadiant Biosciences’ Elapegademase (Revcovi) and Leadiant Biosciences’ Elapegademase (Revcovi). Furthermore, Portola’ Coagulation factor Xa (Andexxa), and Bayer’s Anti-haemophilic factor (JIVI) also received CBER approval.
North American Region Holds the Largest Market Share of the Market and is Believed to Follow the Same Trend over the Forecast Period
North America is expected to lead the global recombinant protein market, owing to the increasing expenditure in research. The United States is anticipated to witness the highest growth, owing to the largest concentration of world-class research universities and academic medical centers. The R&D spending of the United States is around 2.7% of its gross domestic product (GDP). In 2014, the United States was leading the R&D investments in biotechnology and, since then, the US biotechnology research and investment has been growing at a steady rate. The development of new products and collaboration activities of biotechnology companies is likely to boost the growth of the recombinant protein market.
The recombinant protein market consists of several major players, including Eli Lilly and Company, Merck KGaA, and Novo Nordisk AS, among others. The companies are implementing certain strategic initiatives, such as mergers, new product launches, acquisitions, and partnerships, which help them in strengthening their market position. For instance, in July 2018, the Abcam Merck together produced a PD-L1 antibody for immuno-oncology research.
Reasons to Purchase this report:
The market estimate (ME) sheet in Excel format
Report customization as per the client’s requirements
3 months of analyst support
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Expenditure in Research and Development
4.2.2 Growing Prevalence of Chronic Diseases
4.2.3 Rising Inclination toward Biologics and Biosimilars
4.2.4 Advanced Recombinant Products
4.3 Market Restraints
4.3.1 Expensive and Time-consuming Production Process
4.3.2 Safety Issues
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type of Product
5.1.2 Growth Factor
5.1.5 Other Type of Products
5.2 By Application
5.2.1 Research Application
5.2.2 Therapeutic Use
5.2.3 Biotechnology Industry
5.3.1 North America
184.108.40.206 Rest of Europe
220.127.116.11 South Korea
18.104.22.168 Rest of Asia-Pacific
5.3.4 Middle East and Africa
22.214.171.124 South Africa
126.96.36.199 Rest of Middle East and Africa
5.3.5 South America
188.8.131.52 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1.1 Abcam PLC
6.1.2 Amgen Inc.
6.1.3 Bio-Rad Laboratories Inc.
6.1.4 Eli Lilly and Company
6.1.5 Enzo Biochem, Inc (Enzo Life Sciences Inc.)
6.1.6 Merck KGaA
6.1.7 Novo Nordisk AS
6.1.8 ProSpec-Tany TechnoGene Ltd
6.1.9 Sanofi SA
6.1.10 Thermo Fisher Scientific Inc.
7 MARKET OPPORTUNITIES AND FUTURE TRENDS